Background. In high-income countries, inflammation has been associated with increased morbidity and mortality in human immunodeficiency virus (HIV)-infected individuals despite treatment with antiretroviral therapy (ART). However, these findings may not be generalizable to low-income settings.
Morbidity and mortality from human immunodeficiency virus (HIV)-associated but non-AIDS-defining conditions continue to increase despite improved access to effective antiretroviral therapy (ART), especially in low-and middle-income countries [1] and even in virologically suppressed individuals treated with ART [2] [3] [4] [5] . Ongoing systemic inflammation appears to be a major driver of morbidity and mortality among HIV-infected patients [2, 6] . Bacterial translocation across the gastrointestinal mucosal barrier and chronic low-level viral replication are well-described causes of persistent inflammation and may contribute to noninfectious HIV-related comorbidities [7] [8] [9] [10] [11] [12] . For example, biomarkers of monocyte activation and mediators of inflammation including soluble CD14 (sCD14), soluble CD163 (sCD163), and interleukin (IL) 6 have been associated with increased cardiovascular disease risk [13] [14] [15] , cancer [16] , anemia [17] , and death [18, 19] in HIV-infected individuals. Other biomarkers, including matrix metalloproteinases (MMPs), despite previously being identified as potentially associated with noninfectious HIV-associated pathology [20] , have not been robustly examined in this manner or in a cohort from lower-income countries. The combined effects of an aging population and increased morbidity and mortality due to inflammation present an ominous combination to public health systems worldwide [21] , but especially in lower-income settings with a high burden of HIV, such as sub-Saharan Africa.
It is unclear if elevated biomarkers are the cause of increased morbidity and mortality or are reflective of a proinflammatory state leading to increased pathology. If the former, biomarkers could serve as therapeutic targets in the hope of reversing chronic end-organ dysfunction [19, 22, 23] . If the latter, specific biomarkers or a combination could be surrogates in clinical trials of noninfectious disease prevention strategies and prognostic indicators for those infected with HIV [24] .
Associations between inflammatory markers and clinical scoring indices [25, 26] as well as morbidity and mortality [27] have been described in virologically suppressed, HIV-infected populations in high-income countries. However, this relationship has not been well examined in lower-income settings such as sub-Saharan Africa, where recurrent and chronic endemic coinfections can lead to a proinflammatory state that is not commonly observed in high-income countries [28] . Several risk indices have been used in HIV-infected populations in high-income settings to estimate morbidity and/or mortality, including the Veterans Aging Cohort Study (VACS) index [29] , Fibrosis-4 (FIB-4) score [30] , and 10-Year Framingham Cardiovascular Disease Risk Calculator (Framingham score) [31] . These instruments can provide insight into the long-term effects of chronic HIV, providing general estimates of all-cause mortality, liver fibrosis, and cardiovascular disease risk, respectively, even among virologically suppressed participants.
This study of a rural Kenyan population assesses inflammation, as measured by biomarker levels, between treated HIVinfected participants with viral suppression and uninfected participants. The data were evaluated for correlations between inflammatory biomarkers and clinical scoring indices and principal components analysis (PCA) was used to examine whether underlying patterns among the biomarkers might reflect clinically relevant systemic immune activation.
METHODS

Study Design and Participants
For this analysis, adult participants, aged ≥18 years, were selected from 6 clinical sites in Kenya's South Rift Valley (Supplementary Figure 1) participating in the African Cohort Study (AFRICOS). This President's Emergency Plan for AIDS Relief (PEPFAR)-supported prospective study enrolls adults at 11 clinical facilities across 4 African countries (Kenya, Uganda, Tanzania, and Nigeria). HIV-infected participants in this analysis were randomly selected either from existing clinic client rosters (stratified by age and ART status) or were new enrollees to the clinics. HIV-uninfected participants were recruited from voluntary counseling and testing centers, prior studies completed at the clinical site, or represent seronegative partners of HIV-infected participants. For both HIV-infected and -uninfected participants, clinical and laboratory assessments are performed every 6 months. Participant recruitment and enrollment began 21 January 2013 and is ongoing. Institutional review boards of the Kenya Medical Research Institute and the Walter Reed Army Institute of Research approved the study. All participants provided written informed consent.
At enrollment, demographic data were collected, participants underwent a medical history and physical examination, and peripheral phlebotomy was performed for laboratory testing and plasma storage. Participants were divided into 4 groups: HIV-uninfected participants (uninfected), HIV-infected participants on ART with viral load <50 copies/mL (HIV-infected/ suppressed), HIV-infected participants on ART with viral load ≥50 copies/mL (HIV-infected/unsuppressed), and HIVinfected participants not taking ART (HIV-infected/untreated).
Infectious comorbidity testing for all participants included hepatitis B diagnosed by genetic systems (GS) hepatitis B surface antigen (HBsAg) 3.0 enzyme immunoassay (EIA) and GS HBsAg confirmatory assay (Bio-Rad Laboratories), hepatitis C virus (HCV) diagnosed by Ortho Clinical HCV version 3.0 EIA (Ortho Clinical Diagnostics) and INNO-LIA HCV score for confirmation (Fufirebio), and syphilis diagnosed by rapid plasma reagin or Venereal Disease Research Laboratory. Plasma drawn from each participant's enrollment visit was used to measure biomarker levels. Tobacco, alcohol, and drug use were self-reported. For HIV-infected participants, demographic, clinical, and laboratory data from enrollment were used to calculate the VACS index [32] , FIB-4 score [30] , and Framingham score [33] . Platelet count, cholesterol, glucose, and kidney function were only measured in HIV-infected participants, so these clinical scoring indices could not be calculated for HIV-uninfected participants. The only noninfectious comorbidity assessed in all participants was hypertension. Dysglycemia, hypercholesterolemia, and renal insufficiency were only assessed in HIV-infected participants and subsequently could not be compared with the uninfected group. Hypertension was excluded as a covariate in the final model since it could represent an effect and not a cause of inflammation.
Procedures and Laboratory Measurements
This study examined 28 total biomarkers, 26 of which were measured from cryopreserved plasma using commercially available kits. Luminex xMAP multiplex kits (R&D Systems) were used to measure CCL2, CCL4, CCL5, C-reactive protein, colony stimulating factor 2 (CSF2), CXCL10, fatty acid binding protein (FABP) 1, FABP3, fas ligand (FASLG), interferon gamma (IFN-γ), IL-6, IL-10, IL-17A, IL-22, MMP1, MMP2, MMP7, MMP9, MMP12, sCD163, tumor necrosis factor (TNF), tumor necrosis factor receptor superfamily (TNFRSF) 1A, TNFRSF1B, and TNFRSF10, as previously described [34] . Enzyme-linked immunosorbent assay was used to measure FABP2 and sCD14 in plasma (R&D Systems). In real-time, whole blood was screened for T-cell activation using cocktails of commercially available antibodies assayed with a lyse, no wash, sample preparation procedure, acquired on a 2-laser, FACSCalibur (BD Biosciences) to evaluate the percentage of CD4 or CD8 T cells co-expressing CD38 and HLA-DR as previously described [35, 36] . Flow cytometry data analysis was performed using Flow Jo (TreeStar).
Statistical Analyses
Descriptive statistics for the biomarkers were reviewed and biomarkers that exhibited little variability were excluded from further analysis. Kruskal-Wallis tests were used to evaluate differences among the 4 study groups (uninfected, HIV infected/ suppressed, HIV infected/unsuppressed, and HIV infected/ untreated), followed by pairwise group comparisons for biomarkers significant at the α = .01 level using the Dwass, Steel, Critchlow-Fligner procedure. Multivariable linear regression models were fit for the log 2 transformed biomarkers, adjusting for potential confounding variables including age, sex, tribe, hepatitis B, and syphilis. These coinfections were selected since they represent other chronic inflammatory processes that can influence biomarker levels [37, 38] and data were available for all participants, including the uninfected group. Sensitivity of the results to normality assumptions was assessed using ordinal logistic regression models. Principal components analysis was used to determine if there were any patterns (as defined by linear combinations) among the biomarkers that differed across the predefined groups. Biomarkers were mean-centered and scaled to have unit variance before applying PCA. Spearman rank correlations between the biomarkers and the 3 continuous clinical scoring indices were estimated. P values were not adjusted for multiple comparisons, but a significance threshold of α = .01 was used to reduce the number of false-positive discoveries. All statistical analyses were performed in SAS version 9.4 (SAS Institute) or R version 3.3 software.
RESULTS
Participant Characteristics
A total of 304 participants were grouped on prespecified conditions: 79 uninfected (26%), 125 HIV infected/suppressed (41.1%), 39 HIV infected/unsuppressed (12.8%), and 61 HIV infected/untreated (20.1%). Participant characteristics are described in Table 1 . Overall, the mean age was 40.4 years, 58% of participants were female, and participants were primarily from the Kalenjin tribe (68%). Groups were similar in terms of sex and tribal affiliation (a surrogate marker for genetics and ethnicity), whereas a significant difference was observed for age (P < .001), with HIV-infected/suppressed participants tending to be older (mean age, 44 years vs about 38 for the other groups). There was no significant difference between the viral loads of the HIV-infected/unsuppressed and HIV-infected/untreated groups. Although tobacco, alcohol, and drug use are potential confounders, the rates of use were low in our study and not individually associated with biomarkers in pairwise analyses. Therefore, these factors were left out of the multivariable model. HCV was not considered in any analyses because only a single case was identified in the study population.
Biomarkers
Of the 28 inflammatory markers of interest initially evaluated, 9 were excluded from further analyses due to immeasurable levels or lack of variability (CSF2, FABP1, FABP3, IFN-γ, IL-10, IL-17A, MMP12, TNF, TNFRSF10). Of the remaining 19 biomarkers, 12 differed significantly across the 4 groups (all P ≤ .005; Figure 1 and Supplementary Table 1 ). Nine biomarkers were significantly different (all P ≤ .001) between the HIVinfected/untreated and -uninfected groups including CD4 + / HLA-DR + CD38 + , CXCL10, sCD14, and sCD163. Multiple biomarkers including CD8 + /HLA-DR + CD38 + , high-sensitivity IL-6, and TNFRSF1B were similar in pairwise comparisons between the uninfected and HIV-infected/suppressed groups, but were elevated in the HIV-infected/unsuppressed and HIVinfected/untreated groups, suggesting inflammatory processes related to viremia. However, some differences were appreciated in pairwise comparisons between the uninfected and HIVinfected/suppressed groups. For example, compared to the uninfected group, the median values of CD4 + /HLA-DR + CD38 + (1.79% vs 1.17% activation), CXCL10 (34.57 vs 23.23 pg/mL), FABP2 (2870 vs 1405 pg/mL), and sCD14 (1885 vs 1537 ng/ mL) were significantly higher in the HIV-infected/suppressed group (all P < .001), and TNFRSF1A (3579 vs 4562 pg/mL) was significantly lower (P < .003). After adjusting for age, sex, tribe, hepatitis B, and syphilis, the mean log 2 values of CCL5, CXCL10, FABP2, FASLG, sCD14, and sCD163 were all significantly higher (P < .01 for each comparison) in the HIV-infected/ suppressed group compared to the uninfected group (Table 2) . A subset of MMPs, proteolytic enzymes involved in diverse immune activities and abnormally expressed in HIV-infected participants [20] , were quantified and compared between all 4 study groups (Figure 2 ). The HIV-infected/suppressed group had higher median levels of MMP1 (4349 pg/mL) compared to uninfected participants (3195 pg/mL; P = .036, KruskalWallis test, not significant) and MMP7 (2655 vs 2031 pg/mL; P < .001), but decreased levels of MMP9 (19 492 vs 37 616 pg/ mL; P < .001) and all were significant after controlling for age, sex, tribe, hepatitis B, and syphilis.
Principal Components Analysis
PCA was performed to assess the variance among the 19 biomarkers of interest in the 220 participants without any missing values. The components were then examined for possible associations between these underlying patterns in biomarker covariation and the groups of interest (Figure 3 ). The first component had positive coefficients for most biomarkers (Supplementary Table 2 ). Plasma levels of CD4 + /HLA-DR + CD38 + , CD8 + /HLA-DR + CD38 + , CXCL10, and TNFRSF1B contributed the most to component 1, which explained 23.7% of the variability in the data. The second component explained 14% of the variability in biomarker levels, with MMP2 contributing most to this component, followed by CCL4 and MMP1 (all with positive coefficients). The scores for the first 2 principal components (PC) were significantly different between the groups (Kruskal-Wallis test, P < .001 for PC1 and PC2); the uninfected and HIV-infected/ suppressed groups tended to cluster together with lower values, on average, for the first component and higher values for the second (Wilcoxon rank-sum test, P < .001 for each comparison) whereas the HIV-infected/unsuppressed and HIV-infected/ untreated groups tended to cluster together, potentially due to ongoing viremia.
Scoring Indices
The clinical scores for the VACS index, FIB-4, and Framingham risk score were compared across the 3 HIV-infected groups ( Figure 4 ). The VACS index was significantly higher (P < .001) in the HIV-infected/unsuppressed (mean 36.4) compared to the HIV-infected/suppressed group (mean, 26.3). The Framingham risk score was higher (P < .001) in the HIV-infected/suppressed group (mean, 4.6) compared to the other 2 HIV-infected groups, which could be related to the older age of this group (see Supplementary Table 3) . No significant differences in FIB-4 were observed between groups (P = .24).
Spearman rank-order correlations were estimated between the risk indices and the 19 biomarkers (Supplementary Table 4 ). CD4 + /HLA-DR + CD38 + , sCD14, and sCD163 were significantly correlated with the VACS index score among HIV-infected/ suppressed (estimated correlations of 0.32, 0.26, and 0.24, respectively; P ≤ .006 for each comparison) ( Figure 5 ). MMP7 was the only biomarker that was significantly correlated with the Framingham score among HIV-infected/suppressed participants with an estimated Spearman ρ of 0.27 (P = .002). FABP2, MMP1, and MMP2 were significantly correlated with the FIB-4 score within the HIV-infected/suppressed group with correlation coefficients of 0.29, -0.32, and -0.28, respectively (all P < .003).
Further exploratory analysis assessing the relationship between the PCA and scoring indices demonstrated that the VACS index was positively correlated with PC1 (ρ = 0.5; P < .001) and negatively correlated with PC2 (ρ = -0.2; P = .002). The FIB-4 and Framingham scoring indices were not significantly correlated with either component.
DISCUSSION
This study of a rural Kenyan population found heightened levels of several inflammatory biomarkers in virologically suppressed HIV-1-infected participants on ART, as compared to HIVuninfected controls, after adjusting for age, sex, tribe, hepatitis , and infected/untreated (red) groups. The height of the notch represents the 95% confidence interval for the median (bar) while the box represents the 25th-75th median percentiles. Horizontal lines above plots represents significance at P < .01 between groups using the Dwass, Steel, Critchlow-Fligner procedure for pairwise comparisons. The upper whisker represents 1.5 times the interquartile distance from the 75th percentile, while the lower whisker represents 1.5 times the interquartile distance from the 25th percentile. The dot symbols represent outliers above the upper or below the lower whiskers. Abbreviations: FABP, fatty acid binding protein; hsIL-6, high-sensitivity interleukin 6; sCD14, soluble CD14; sCD163, soluble CD163; TNFRSF, tumor necrosis factor receptor superfamily.
B, and syphilis. Although the inflammatory profiles of uninfected and HIV-infected/suppressed groups were more similar to each other than the other HIV-infected groups as seen in the PCA, statistically significant differences in some biomarker levels were observed between these 2 groups. The HIV-infected/ untreated and HIV-infected/unsuppressed groups clustered near each other on the PCA and there were no statistically significant differences (all P ≥ .02) in pairwise comparison for any of the biomarkers between these 2 groups. These results confirm in a low-income setting previously reported inflammatory biomarker relationships among well-controlled HIV-infected patients on ART and uninfected controls from high-income countries [39] . This study evaluated primarily heterosexual transmission, which may be different from studies of same-sex transmission or intravenous drug use. Furthermore, our cohort may differ from other cohorts in host and viral genetics, sex differences, climate, diet, and endemic disease, all of which could contribute to levels of inflammation and immune activation. The difference in biomarker levels can be difficult to demonstrate in a low-income setting where immune system activation is higher in HIV-1-uninfected individuals compared to studies in the United States and Europe, in part due to due to infections from a diverse array of endemic pathogens [28, 40] . New insights were gained by examining a broad array of biomarkers in participants from a lower-income country. For example, the significantly increased levels of MMP1 and MMP7 and decreased levels of MMP9 in the linear regression models have not been described previously and their involvement in the residual inflammatory state of HIV-infected/ suppressed patients should be further studied. Additionally, the biomarkers sCD14 and sCD163 have been associated with monocyte/macrophage activation [3, 23] . However, other markers of monocyte activation including CCL2, CCL4, and granulocyte macrophage colony-stimulating factor were not significantly elevated between the HIV-infected/suppressed group and uninfected participants or related to the scoring indices that were measured, suggesting specificity in the inflammatory process. Select biomarkers were not only different between the uninfected and HIV-infected/suppressed group but were correlated with clinical scoring indices predictive of morbidty and mortalily. CD4 + /HLA-DR + CD38 + , sCD14, and sCD163 were present in higher levels in the HIV-infected/suppressed group and had some of the highest statistically significant Spearman correlations with the VACS index of 0.32 (P < .001), 0.26 (P = .004), and 0.24 (P = .006), respectively. This occurred in the HIV-infected/suppressed group despite being on therapy an average of 4.5 years, which could have altered biomarker levels [41, 42] . Both sCD14 and sCD163 were previously reported as elevated in well-controlled HIVinfected participants from high-income countries and related to morbidity and mortality [26] . The VACS index has been validated to predict mortality and frailty for those infected with HIV including those of color [43] , strengthening a possible association between elevated sCD14 and sCD163 with HIV-associated morbidity and mortality in a Kenyan population as well.
FABP2 (ρ = 0.29; P = .002), MMP1 (ρ = -0.32; P < .001), and MMP2 (ρ = -0.28; P = .002) were significantly correlated with FIB-4 scores and MMP7 was significantly correlated with the Framingham score in HIV-infected/suppressed participants. FABP2, which has been predictive of mortality in high-income countries, can be a surrogate for microbial translocation across the gastrointestinal mucosa representing increased gut epithelial cell turnover [44] . Its association with a scoring system that assesses liver fibrosis fits with a theory of microbial translocation since intestinally derived proinflammatory products could cause local inflammation in the intestine prior to passing through the liver via the venous portal circulation [22] . Additionally, the significant inverse correlation of MMP1 and MMP2 with FIB-4 score and significant positive correlation of MMP7 with the Framingham score risk score demonstrate an association between MMPs and clinical scoring indices. How these endopeptidases are involved in pathogen clearance, monocyte migration, and immune regulation in HIV-infected individuals and those who are well-controlled on ART is an area primed for further research.
Study limitations include its cross-sectional design, which precludes evaluation of causality. Unfortunately, existing study data did not permit a longitudinal assessment with definitive outcomes on the development of comorbidities and mortality; therefore, clinical scoring indices were adopted as endpoints. These indices were created in high-income countries and their applicability to populations from lower-income settings is uncertain. Also, not all data were obtained to calculate the indices for the uninfected group. Technical limitations involving a broad survey of soluble factors may limit the sensitivity or specificity of certain markers, as the dynamic range may be narrower. Each biomarker was only evaluated once, failing to capture fluctuations of biomarker levels within participants, although prior data suggest that variability is minimal after a year of viral suppression on ART [45] . Statistically significant differences were apparent for multiple inflammatory biomarkers including CCL5, CXCL10, FABP2, FASLG, MMP1, MMP7, MMP9, sCD14, and sCD163 between the uninfected and HIV-infected/suppressed groups. These elevated biomarkers likely represent a chronic state of immune activation and cytokine dysregulation associated with HIV disease. The observed correlation between elevated levels of CD4 + T-cell activation, sCD14, and sCD163 with higher VACS index scores suggests that ongoing inflammation may be associated with HIV-related morbidity and mortality. The significant correlations of FABP2, MMP1, and MMP2 in the HIV-infected/ suppressed group with the FIB-4 score argue for a possible relationship with liver fibrosis, specifically. The inverse correlations of MMP1 and MMP2 could be explained by an antifibrotic role and suppression of collagen type 1 expression leading to decreased liver fibrosis and subsequent lower FIB-4 scores [46] .
Ongoing residual inflammatory biomarkers and an association with clinical scoring indices evaluating morbidity and mortality in well-controlled HIV-infected individuals can be extended to a lower-income setting in sub-Saharan Africa. These particular biomarkers are perhaps the most appropriate targets for potential therapeutic anti-inflammatory agents. A specific approach targeting monocyte activation or gastrointestinal microbial translocation could minimize unnecessary systemic anti-inflammatory side effects in an attempt to control residual HIV-related inflammation. Another potential application could be using these specific biomarkers or a collection of them as a surrogate in clinical trials. Further research is needed to validate clinical scoring indices in HIV-infected African populations, clarify the relationship between biomarkers and morbidity and mortality, and evaluate their potential as prognostic markers and therapeutic targets within the inflammatory pathway.
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